RNA CART-cMET

RNA CART-cMET is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by the University of Pennsylvania for the treatment of advanced malignancies, specifically metastatic melanoma and triple-negative breast cancer. Unlike traditional CAR T-cell therapies that use viral vectors for permanent genetic modification, RNA CART-cMET utilizes RNA electroporation of in vitro transcribed mRNA to achieve transient expression of the CAR. The CAR construct targets the cMET (hepatocyte growth factor receptor) protein, which is frequently overexpressed in various solid tumors. The signaling domain includes the 4-1BB (CD137) costimulatory domain and the CD3-zeta chain. This transient approach is designed as a safety feature to mitigate potential long-term toxicities while allowing for multiple systemic administrations without the need for lymphodepleting chemotherapy.

Other names

T cells modified with RNA anti-cMET CARcMET-directed RNA CAR T cells